ZLD Chart, page-17

"The company also received its maiden revenues from Advanced Biomedicsfor its first licensing deal
for HOPETM in the United States (US), which was announced in December 2019. Advanced Biomedics has
commenced plans to launch HOPE later in 2020."

The above is from the March quarterly report. I hope this answers your question. The revenue in that quarter was the upfront licensing fee, it was not from sales.

"In December 2019, Zelira announced its maiden post-merger licensing transaction and inaugural revenues
in the United States when it entered into an agreement with Advanced Biomedics to license HOPE® into
Louisiana, a state with approximately 5 million residents. The agreement includes an upfront payment,
that was paid in Q1 2020, and ongoing royalties on sales, which are expected to commence from mid2020. Zelira expects to announce multiple licensing deals in 2020 as it continues to roll-out HOPE® in
other US-states."

This is from the Dec quarterly report. It states that sales are expected to start mid 2020. Going by press ex Louisiana, it would seem sales of Hope in that state started in July 2020.